BR9806912A - Processos para liberar um ou mais ácidos nucleicos em neurÈnios motores de mamìferos, para produzir proteìna em neurÈnios motores de mamìferos, para induzir nós periféricos ou colaterais de extremidades de axÈnios motores, para proteger contra degeneração axÈnica, para tratar um dano ao sistema nervoso, e, para tratar esclerose lateral amiotrófica. - Google Patents

Processos para liberar um ou mais ácidos nucleicos em neurÈnios motores de mamìferos, para produzir proteìna em neurÈnios motores de mamìferos, para induzir nós periféricos ou colaterais de extremidades de axÈnios motores, para proteger contra degeneração axÈnica, para tratar um dano ao sistema nervoso, e, para tratar esclerose lateral amiotrófica.

Info

Publication number
BR9806912A
BR9806912A BR9806912-8A BR9806912A BR9806912A BR 9806912 A BR9806912 A BR 9806912A BR 9806912 A BR9806912 A BR 9806912A BR 9806912 A BR9806912 A BR 9806912A
Authority
BR
Brazil
Prior art keywords
mammalian
motor neurons
treat
processes
nucleic acids
Prior art date
Application number
BR9806912-8A
Other languages
English (en)
Inventor
Francoise Finiels
Minerva Gimenez-Ribotta
Jacques Mallet
Alain Privat
Freduric Revah
Original Assignee
Rhone Poulenc Rorer Sa
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/785,074 external-priority patent/US6632427B1/en
Application filed by Rhone Poulenc Rorer Sa, Inst Nat Sante Rech Med filed Critical Rhone Poulenc Rorer Sa
Publication of BR9806912A publication Critical patent/BR9806912A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"PROCESSOS PARA LIBERAR UM OU MAIS áCIDOS NUCLEICOS EM NEURÈNIOS MOTORES DE MAMìFEROS, PARA PRODUZIR PROTéINA EM NEURÈNIOS MOTORES DE MAMìFEROS, PARA INDUZIR NóS PERIFéRICOS OU COLATERAIS DE EXTREMIDADES DE AXÈNIOS MOTORES PARA PROTEGER CONTRA DEGENERAçãO AXÈNICA, PARA TRATAR UM DANO AO SISTEMA NERVOSO, E, PARA TRATAR ESCLEROSE LATERAL AMIOTRóFICA". A presente invenção refre-se a processos e composições para liberar ácidos nucleicos a neurónios motores administrando os ácidos nucleicos ao tecido muscular. A invenção refere-se a processos para tratar patologias do sistema nervoso, como trauma ou doenças degenerativas.
BR9806912-8A 1997-01-17 1998-01-16 Processos para liberar um ou mais ácidos nucleicos em neurÈnios motores de mamìferos, para produzir proteìna em neurÈnios motores de mamìferos, para induzir nós periféricos ou colaterais de extremidades de axÈnios motores, para proteger contra degeneração axÈnica, para tratar um dano ao sistema nervoso, e, para tratar esclerose lateral amiotrófica. BR9806912A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/785,074 US6632427B1 (en) 1994-12-13 1997-01-17 Adenoviral-vector-mediated gene transfer into medullary motor neurons
US4224797P 1997-03-31 1997-03-31
PCT/EP1998/000220 WO1998031395A1 (en) 1997-01-17 1998-01-16 Adenoviral-vector-mediated gene transfer into medullary motor neurons

Publications (1)

Publication Number Publication Date
BR9806912A true BR9806912A (pt) 2000-05-16

Family

ID=26719029

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9806912-8A BR9806912A (pt) 1997-01-17 1998-01-16 Processos para liberar um ou mais ácidos nucleicos em neurÈnios motores de mamìferos, para produzir proteìna em neurÈnios motores de mamìferos, para induzir nós periféricos ou colaterais de extremidades de axÈnios motores, para proteger contra degeneração axÈnica, para tratar um dano ao sistema nervoso, e, para tratar esclerose lateral amiotrófica.

Country Status (11)

Country Link
US (1) US6552003B2 (pt)
EP (1) EP0969875B1 (pt)
JP (1) JP2002516607A (pt)
AU (1) AU6614398A (pt)
BR (1) BR9806912A (pt)
CA (1) CA2277869A1 (pt)
CZ (1) CZ250499A3 (pt)
IL (1) IL130852A0 (pt)
NO (1) NO993465L (pt)
SK (1) SK95599A3 (pt)
WO (1) WO1998031395A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001076620A2 (en) 2000-04-12 2001-10-18 Vlaams Interuniversitair Instituut Voor Biotecnologie Vzw Use of vegf and homologues to treat neuron disorders
US20050032219A1 (en) * 2001-07-03 2005-02-10 Patrick Aubourg Methods of administering vectors to synaptically connected neurons
AU2002359786A1 (en) * 2001-12-19 2003-07-09 Hiroaki Mizukami Adeno-associated virus-mediated delivery of gdnf to skeletal muscles
JP2007513968A (ja) * 2003-12-12 2007-05-31 ウイスコンシン アラムニ リサーチ ファンデーション 哺乳動物神経細胞へのｓｉＲＮＡのデリバリー
RS51481B (en) 2004-05-27 2011-04-30 Vib, Vzw TREATMENT OF AMIOTROPHIC LATERAL SCLEROSIS
US9078808B2 (en) * 2009-03-26 2015-07-14 Warsaw Orthopedic, Inc. Device to deliver magnesium in PEG formulation
WO2021163274A1 (en) * 2020-02-11 2021-08-19 The General Hospital Corporation Methods for treating amyotrophic lateral sclerosis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
GR1000980B (el) * 1989-08-30 1993-03-31 Max Planck Gesellschaft Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο.
US5849571A (en) * 1990-10-10 1998-12-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Latency active herpes virus promoters and their use
FR2727867B1 (fr) * 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
AU2677797A (en) * 1996-04-25 1997-11-12 Genetic Therapy, Inc. Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor

Also Published As

Publication number Publication date
US6552003B2 (en) 2003-04-22
IL130852A0 (en) 2001-01-28
NO993465D0 (no) 1999-07-14
WO1998031395A1 (en) 1998-07-23
EP0969875A1 (en) 2000-01-12
CZ250499A3 (cs) 1999-11-17
CA2277869A1 (en) 1998-07-23
NO993465L (no) 1999-09-09
EP0969875B1 (en) 2008-11-26
JP2002516607A (ja) 2002-06-04
SK95599A3 (en) 2000-05-16
AU6614398A (en) 1998-08-07
US20020164303A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
EP0831848A4 (en) METHOD FOR TREATING LUNG DISEASES WITH ANTISENSE OLIGONUCLEOTIDES
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
PT815218E (pt) Oligonucleotido anti-sentido especificos para vegf humano
BR9507506A (pt) Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
BR0316157A (pt) Derivados de 4-amino-5-fenil-7-ciclohexil-pirrolo[2,3-d]pirimidina
BR9106826A (pt) Oligonucleotideo ou analogo de oligonucleotideo,processo para modular a producao de uma proteina por um organismo,para tratar um organismo e processos para sintetizar:9(2'-desoxi-2'-substituido-beta-d-ribofuranosil)-guanina e g('-desoxi-2'-fluor-beta-d-ribofuranosil)-guanina
DE60042137D1 (de) Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen
GB9402857D0 (en) Targeting gene therapy
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
DE69617856D1 (de) Methoden zur behandlung von atemwegserkrankungen
DE69532406D1 (de) Neuartige therapeutische und diätetische verwendungen des auf phospholipiden der hirnsabstanz basierenden komplexes
BR9808100A (pt) Utilização de amandantina para tratamento de hepatite c.
BR9806912A (pt) Processos para liberar um ou mais ácidos nucleicos em neurÈnios motores de mamìferos, para produzir proteìna em neurÈnios motores de mamìferos, para induzir nós periféricos ou colaterais de extremidades de axÈnios motores, para proteger contra degeneração axÈnica, para tratar um dano ao sistema nervoso, e, para tratar esclerose lateral amiotrófica.
BR9710173A (pt) Processo de preparação de dna utilizável em terapia gênica utilização de um dna plasmático para a preparaç~o de uma composição farmacêutica destinada ao tratamento terapêutico ou ao diagnóstico do corpo humano ou animal processo de preparação desta composição farmacêutica e composição compreendendo um dna bacteriano
Latha et al. Efficacy of yoga therapy in the management of headaches.
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
FI973023A0 (fi) Liikakasvusairauksien yhdistetty terapeuttinen hoito
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
DE69625919D1 (de) Verwendung von zyklodextrine zur modulierten genexpression mit reduzierter immunostimulation
NO991292L (no) Anvendelse av benzopyranoler for Õ behandle nevrologiske forstyrrelser
BR9908716A (pt) Tratamento de disfunção sexual em certos grupos de pacientes
CA2323213A1 (en) Treatment of respiratory disease and otitis media
ATE255411T1 (de) Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose
AU1601499A (en) Citicoline to treat motor neuron diseases and demyelinating diseases

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO, DE ACORDO COM ARTIGO 8O DA LPI